News
Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...
Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.
5d
Zacks.com on MSNPharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline UpdatesLLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine ...
Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...
Eli Lilly and Company and SiteOne Therapeutics, Inc., a private biotechnology company developing small molecule inhibitors of ...
Detailed price information for Bank of Montreal (BMO-N) from The Globe and Mail including charting and trades.
Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...
Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...
BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...
Asad Haider, head of the healthcare business unit within Goldman Sachs Research, now forecasts the market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, to ...
Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results